

**Abstract Number:** [765]

**Abstract Title:** Clinical outcomes and treatment strategy of multiple sclerosis in China: Results from a real-world cross-sectional survey

**Abstract Category:** Clinical aspects of MS and related diseases - 08 - Epidemiology

**Preferred Presentation Type:** Oral or poster presentation

Xiao Zhang\*<sup>1</sup>, Shuang Cai<sup>1</sup>, Jie Cai<sup>1</sup>, Yuxiang Yang<sup>1</sup>, Wenhao Wang<sup>1</sup>, Eddie Jones<sup>2</sup>, Mia Berry<sup>2</sup>

<sup>1</sup>Novartis Pharma AG, Beijing, China, <sup>2</sup>Adelphi real world, Manchester, United Kingdom

### **Introduction:**

Multiple sclerosis (MS) is a leading cause of disability, affecting especially young adults. The data on clinical outcome, such as no evidence of disease activity (NEDA) and treatment strategies remains very limited in China.

### **Objectives/Aims:**

In this study, we aim to describe status of diagnosis, treatment, and clinical outcomes in patients with MS, as well as treatment strategies in neurologists in real-world clinical setting in China.

### **Methods:**

This study is a secondary data analysis of data collected by Adelphi MS Disease Specific Program (DSP), a cross-sectional survey conducted among neurologists (n=160) and their MS patients (n=956) in different district of China between June and August 2021.

### **Results:**

In preventive treatment, 30.1% patients received the disease modifying treatment (DMT). Among these patients, the percentage of patients with progressive MS is higher than that of patients with relapsing-remitting MS (RRMS) (secondary progressive MS [SPMS]: 36.9%, primary progressive MS [PPMS]: 41.5%; RRMS:28.0%). The mean duration from diagnosis to receiving DMT was 3.7±3.8 years, and this duration in SPMS was the longest (8.0±4.8 years). Among 540 patients with complete follow-up data, 27.4% patients achieved no evidence of disease activity (NEDA)-3 in the past 12 months. In addition, among 160 neurologists, when patients had 1 relapse, disability progression without relapse and active lesions in MRI without relapse, 42.2%, 39.1% and 62.1% neurologists continued the current treatment respectively.

### **Conclusion:**

In China, the percentages of MS patients achieving NEDA-3 were low. This might be due to the low percentage, the late initiation and conservative switching of DMT.

**Disclosures:** Nothing to disclose

**Travel / Abstract Grant Application and Young Scientific Investigators' Session:** I will not apply for Travel Grant or Young Scientific Investigators' Session

# MSMilan2023

9th Joint ECTRIMS-ACTRIMS Meeting  
11–13 October 2023 | Milan, Italy



**Which one would you like to apply to:**

**Date of Birth:**